Press release Biocartis Group NV

Four Abstracts Showing Excellent Data for Idylla Presented at European Society of Molecular Oncology Congress (ESMO) - Seite 2

The fourth abstract⁵ describes a research project that aims to identify the feasibility of the Idylla GeneFusion Assay in detecting RET fusions in Papillary Thyroid Cancer (PTC).

Roger Moody, Chief Executive Officer of Biocartis, commented: “I am proud that independent researchers confirm the excellent performance of our products, especially the studies on the Idylla GeneFusion Assay, which demonstrates that this assay can be valuable for various cancer indications. The confirmation of the low invalid rates of our products in combination with their fast time to result, are a confirmation of the benefits of our Idylla Platform compared to other technologies such as NGS.”

The four study abstracts on Idylla which have been selected for ESMO, can be downloaded here: https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal_2/presenta ...

        

--- END ---

More information:

Investor Relations Biocartis
e-mail        [e-mail]

About Biocartis

With its revolutionary and proprietary Idylla Platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla Platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast and liver cancer, as well as for sepsis. More information: www.biocartis.com. Follow us on X (Twitter): @Biocartis_.

Idylla Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, cleared for sales in the US and registered in many others countries. Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.